The February advisory committee hearing for cranial electrotherapy stimulator (CES) devices was chock full of controversy during the course of the hearing, but one of the companies with an offering in this space is arguing that FDA violated its own rules in the conduct of the hearing and has filed a citizen's petition regarding FDA's proposed classification of CES devices as class III devices. Read More
